Clinical outcomes of second-line treatment following first-line VEGFR-TKI failure in patients with metastatic renal cell carcinoma: a comparison of axitinib alone and axitinib plus anti-PD-1 antibody.

ABSTRACT:

SUBMITTER: Huang J 

PROVIDER: S-EPMC8504141 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature